The beneficial effect of α-glucosidase inhibitor on glucose variability compared with sulfonylurea in Taiwanese type 2 diabetic patients inadequately controlled with metformin: Preliminary data

Journal of Diabetes and its Complications

Volumn 25, Issue 5, 2011, Pages 332-338

  Lin, Shi Dou ^a   Wang, Jun Sing ^b   Hsu, Shang Ren ^a   Sheu, Wayne H H ^b,c,d,e   Tu, Shih Te ^a   Lee, I Te ^b,c,d   Su, Shih Li ^a   Lin, Shih Yi ^b,c   Wang, Shu Yi ^a   Hsieh, Ming Chia ^a,d,f  

^a CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^b TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^e NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^f CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Acarbose; Continuous glucose monitoring; Glucose variability; Sulfonylurea; Type 2 diabetes

Indexed keywords

ACARBOSE; GLIBENCLAMIDE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; SULFONYLUREA;

ABDOMINAL DISTENSION; ACUTE HEART INFARCTION; ADD ON THERAPY; ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; DIZZINESS; DRUG EFFECT; DRUG INDUCED HEADACHE; DYSPNEA; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; LOW BACK PAIN; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHOULDER PAIN; TAIWAN; UPPER GASTROINTESTINAL BLEEDING; WEIGHT REDUCTION;

ACARBOSE; ADULT; AGED; ALPHA-GLUCOSIDASES; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; MONITORING, AMBULATORY; TAIWAN; WEIGHT LOSS;

EID: 80052706816     PISSN: 10568727     EISSN: 1873460X     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2011.06.004     Document Type: Article

References (38)

1. N.A. Ali, J.M. O'Brien, K. Dungan, G. Phillips, C.B. Marsh, and S. Lemeshow Glucose variability and mortality in patients with sepsis Critical Care Medicine 36 2008 2316 2321
2. Y.Q. Bao, J. Zhou, M. Zhou, Y.J. Cheng, W. Lu, and X.P. Pan Glipizide controlled-release tablets, with or without acarbose, improve glucose variability in newly diagnosed type 2 diabetes Clinical and Experimental Pharmacology & Physiology 37 2010 564 568
3. J.B. Buse, M.H. Tan, M.J. Prince, and P.P. Erickson The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes Diabetes, Obesity & Metabolism 6 2004 133 156 (Pubitemid 38220106)
4. Canadian Diabetes Association Clinical practice guidelines http://www.diabetes.ca/for-professionals/resources/2008-cpg/ 2008
5. A. Ceriello Postprandial hyperglycemia and diabetes complications: Is it time to treat? Diabetes 54 2005 1 7 (Pubitemid 40105088)
6. A. Ceriello, and S. Colagiuri International Diabetes Federation guideline for management of postmeal glucose: A review of recommendations Diabetic Medicine: a Journal of the British Diabetic Association 25 2008 1151 1156
7. A. Ceriello, and M.A. Ihnat 'Glycemic variability': A new therapeutic challenge in diabetes and the critical care setting Diabetic Medicine: a Journal of the British Diabetic Association 27 2010 862 867
8. J.L. Chiasson, R.G. Josse, R. Gomis, M. Hanefeld, A. Karasik, M. Laakso STOP-NIDDM Trial Research Group Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial JAMA: The Journal of the American Medical Association 290 2003 486 494 (Pubitemid 37430502)
9. G. Derosa, P. Maffioli, I. Ferrari, E. Fogari, A. D'Angelo, and I. Palumbo Acarbose actions on insulin resistance and inflammatory parameters during an oral fat load European Journal of Pharmacology 651 2011 240 250
10. K.M. Dungan, J.B. Buse, J. Largay, M.M. Kelly, E.A. Button, and S. Kato 1,5-Anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes Diabetes Care 29 2006 1214 1219 (Pubitemid 44125912)
11. S. Fischer, A. Patzak, H. Rietzsch, U. Schwanebeck, C. Köhler, and J. Wildbrett Influence of treatment with acarbose or glibenclamide on insulin sensitivity in type 2 diabetic patients Diabetes, Obesity & Metabolism 5 2003 38 44 (Pubitemid 36367476)
12. S. Halimi, M.A. Le Berre, and V. Grangé Efficacy and safety of acarbose add-on therapy in the treatment of overweight patients with type 2 diabetes inadequately controlled with metformin: a double-blind, placebo-controlled study Diabetes Research and Clinical Practice 50 2000 49 56 (Pubitemid 30629019)
13. M. Hanefeld, M. Cagatay, T. Petrowitsch, D. Neuser, D. Petzinna, and M. Rupp Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: Meta-analysis of seven long-term studies European Heart Journal 25 2004 10 16 (Pubitemid 38055587)
14. S.E. Inzucchi Oral antihyperglycemic therapy for type 2 diabetes: Scientific review JAMA: The Journal of the American Medical Association 287 2002 360 372 (Pubitemid 34256388)
15. D.C. Klonoff Continuous glucose monitoring: roadmap for 21st century diabetes therapy Diabetes Care 28 2005 1231 1239 (Pubitemid 40616646)
16. Y. Li, L. Xu, J. Shen, J. Ran, Y. Zhang, and M. Wang Effects of short-term therapy with different insulin secretagogues on glucose metabolism, lipid parameters and oxidative stress in newly diagnosed type 2 diabetes mellitus Diabetes Research and Clinical Practice 88 2010 42 47
17. C.M. McDonnell, S.M. Donath, S.I. Vidmar, G.A. Werther, and F.J. Cameron A novel approach to continuous glucose analysis utilizing glycemic variation Diabetes Technology & Therapeutics 7 2005 253 263 (Pubitemid 40586369)
18. G.D. Molnar, W.F. Taylor, and M.M. Ho Day-to-day variation of continuously monitored glycemia: a further measure of diabetic instability Diabetologia 8 1972 342 348
19. L. Monnier Is postprandial glucose a neglected cardiovascular risk factor in type 2 diabetes? European Journal of Clinical Investigation 30 Suppl 2 2000 3 11 (Pubitemid 30604060)
20. L. Monnier, C. Colette, and D.R. Owens Glycemic variability: the third component of the dysglycemia in diabetes. Is it important? How to measure it? J Diabetes Sci Technol 2 2008 1094 1100
21. L. Monnier, E. Mas, C. Ginet, F. Michel, L. Villon, and J.P. Cristol Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes JAMA: The Journal of the American Medical Association 295 2006 1681 1687
22. T. Nakagami DECODA Study Group Hyperglycemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin Diabetologia 47 2004 385 394 (Pubitemid 38491233)
23. D.M. Nathan, J.B. Buse, M.B. Davidson, E. Ferrannini, R.R. Holman, and R. Sherwin American Diabetes Association; European Association for the Study of Diabetes Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes Diabetologia 52 2009 17 30
24. D.M. Nathan, J.B. Buse, M.B. Davidson, R.J. Heine, R.R. Holman, and R. Sherwin Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 29 2006 1963 1972 (Pubitemid 44156663)
25. NICE Guidance Type 2 diabetes http://guidance.nice.org.uk/CG66 2008
26. P. Phillips, J. Karrasch, R. Scott, D. Wilson, and R. Moses Acarbose improves glycemic control in overweight type 2 diabetic patients insufficiently treated with metformin Diabetes Care 26 2003 269 273 (Pubitemid 36929042)
27. A. Qaseem, S. Vijan, V. Snow, J.T. Cross, K.B. Weiss, D.K. Owens, and Clinical Efficacy Assessment Subcommittee of the American College of Physicians Glycemic control and type 2 diabetes mellitus: The optimal hemoglobin A1c targets. A guidance statement from the American College of Physicians Annals of Internal Medicine 147 2007 417 422 (Pubitemid 351664542)
28. A.D. Rao, N. Kuhadiya, K. Reynolds, and V.A. Fonseca Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality? A meta-analysis of observational studies Diabetes Care 31 2008 1672 1678
29. D. Rodbard Interpretation of continuous glucose monitoring data: Glycemic variability and quality of glycemic control Diabetes Technology & Therapeutics 11 Suppl 1 2009 S55 67
30. J.H. Scarpello, and H.C. Howlett Metformin therapy and clinical uses Diabetes & Vascular Disease Research: Official Journal of the International Society of Diabetes and Vascular Disease 5 2008 157 167
31. F.J. Service, G.D. Molnar, J.W. Rosevear, E. Ackerman, L.C. Gatewood, and W.F. Taylor Mean amplitude of glycemic excursions, a measure of diabetic instability Diabetes 19 1970 644 655
32. M. Shimabukuro, N. Higa, I. Chinen, K. Yamakawa, and N. Takasu Effects of a single administration of acarbose on postprandial glucose excursion and endothelial dysfunction in type 2 diabetic patients: A randomized crossover study Journal of Clinical Endocrinology and Metabolism 91 2006 837 842 (Pubitemid 43357747)
33. R. Tanenberg, B. Bode, W. Lane, C. Levetan, J. Mestman, and A.P. Harmel Use of the Continuous Glucose Monitoring System to guide therapy in patients with insulin-treated diabetes: A randomized controlled trial Mayo Clinic Proceedings 79 2004 1521 1526 (Pubitemid 39578876)
34. T.S. Temelkova-Kurktschiev, C. Koehler, E. Henkel, W. Leonhardt, K. Fuecker, and M. Hanefeld Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level Diabetes Care 23 2000 1830 1834
35. The NAVIGATOR Study Group Effect of nateglinide on the incidence of diabetes and cardiovascular events New England Journal of Medicine 362 2010 1463 1476
36. F.A. Van de Laar, P.L. Lucassen, R.P. Akkermans, E.H. Van de Lisdonk, G.E. Rutten, and C. Van Weel Alpha-glucosidase inhibitors for type 2 diabetes mellitus Cochrane Database of Systematic Reviews 2 2005 1 173
37. J.S. Wang, S.T. Tu, I.T. Lee, S.D. Lin, S.Y. Lin, and S.L. Su Contribution of postprandial glucose to excess hyperglycaemia in Asian type 2 diabetic patients using continuous glucose monitoring Diabetes/Metabolism Research and Reviews 27 2011 79 84
38. J. Zhou, W. Jia, Y. Bao, X. Ma, W. Lu, and H. Li Glycemic variability and its responses to intensive insulin treatment in newly diagnosed type 2 diabetes Medical Science Monitor: International Medical Journal of Experimental and Clinical Research 14 2008 CR552 CR558